In April almost $1 billion was wiped from the combined market value of four well-regarded companies: Acrux, Mesoblast, QrXPharma and Prana Biotechnology, dragging down equally well known names such as Waislitz and Liberman.
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
The portfolios of some of Australia’s richest investors have been battered by the terrible start to the year experienced by biotechnology stocks.
In April, almost $1 billion was wiped from the combined market value of four companies, Acrux , Mesoblast , QrXPharma and Prana Biotechnology , dragging down equally well known names like Waislitz, Liberman, Smorgon and Walker.
Fetching latest articles
Original URL: https://www.afr.com/companies/healthcare-and-fitness/rich-list-names-hurt-by-cruel-april-for-biotech-stocks-20140505-iu0eh